Conditional acceleration does not lower review standards or guarantee approval

Ten measures address initial, change and renewal applications

Liaoning's medical products regulator issued a trial fast-review list on July 30, 2026, effective upon publication. Its ten measures cover recognized innovative and priority devices, certain Class II products brought into local production, eligible changes and renewals. The list combines accelerated handling with defined dossier relief and narrower quality-system inspection requirements in specific cases. It does not establish a universal accelerated deadline, waive substantive review standards or guarantee approval. Applicants should identify the provision that matches their product and proposed change.

Eligibility depends on the project and product history

Recognized Class II innovative and priority products follow their respective expedited procedures. Class II products already marketed in another province or imported may receive accelerated registration and production licensing when brought into production in Liaoning, provided the dossier is complete and the product has no substantive change. Eligible clinical innovation conversion projects and specified changes during the first registration cycle also qualify.

Dossier relief must match the actual change

The list specifies exemptions from certain testing, performance, stability and clinical evaluation materials for eligible IVD changes not expected to add risk. Shelf-life-only changes have a separate exemption list and should not be treated as interchangeable with packaging-size changes. Where design, materials, manufacturing processes, indications or methods of use change, quality-system inspection focuses on the changed elements; other changes are exempt from that inspection.

A late renewal still requires a new initial application

Applicants that miss the six-month pre-expiry renewal window and reapply through initial registration may use their most recent clinical evaluation and registration testing materials if the production address, conditions and product remain substantively unchanged. Testing reports must meet current mandatory standards and regulatory requirements. Regulix recommends documenting separately the basis for accelerated handling and the basis for each requested dossier exemption.